Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
PUR003 · 2 trials · 4 indications
| Arm | Type | Description |
|---|---|---|
| placebo | PLACEBO_COMPARATOR | normal saline for inhalation |
| PUR003 | ACTIVE_COMPARATOR | PUR003 for inhalation |
| Name | Type | Description |
|---|---|---|
| PUR003 | DRUG | PUR003 for inhalation |
| Placebo | DRUG | Normal saline for inhalation |
Inclusion Criteria: 1. Signed written informed consent. 2. Ability and willingness to return to the outpatient clinic for repeated clinic visits and complete all assessments. 3. Adult male or female subject, 18-60 years of age. 4. Stable, mild asthma not requiring any medical treatment other than s...
PUR003 is an investigational small molecule being studied for use in asthma and in healthy adults. It is administered by inhalation. The drug is in Phase 1 clinical development and has not been approved by the FDA.
PUR003 is being developed by Pulmatrix, Inc., a biopharmaceutical company traded on the NASDAQ under the ticker PULM. The company is conducting clinical trials of the drug in respiratory conditions.
PUR003 is in Phase 1 clinical development. Two Phase 1 trials have been completed, one in healthy adults and one in patients with asthma. The drug remains investigational and has not received regulatory approval.
PUR003 has been studied in two completed Phase 1 trials. NCT00947687 evaluated the safety and efficacy of inhaled PUR003 on a controlled influenza virus challenge in healthy adults in the United Kingdom. NCT00989521 evaluated the effect of PUR003 on asthma in Canada.
PUR003 is the sole name used for this investigational drug in the clinical trial records. No alternative names have been reported for the compound.